Epitel Raises $26M to Expand Wireless EEG Monitoring

Epitel closed a $26M Series B to expand REMI, its wearable wireless remote EEG monitoring system. Catalyst Health Ventures and Genoa Ventures co-led the round, with participation from other new and existing investors that were not named.

The funding matters because Epitel is moving from regulatory progress to commercial execution. The company says the REMI portfolio has secured five FDA 510(k) clearances, and the Series B will finance sales, customer experience, provider adoption, distribution, deployment, and broader ambulatory access.

That changes the central question. Epitel no longer needs only to prove that wireless EEG can clear regulatory review. It now has to demonstrate that hospitals, neurology practices, clinicians, and patients can adopt extended monitoring without turning a longer stream of data into a heavier clinical workflow.

What Happened

Epitel announced the financing on July 28, 2026. The company said the capital will expand its commercial infrastructure, streamline how clinical teams integrate REMI into existing workflows, and increase access to ambulatory monitoring, including for patients as young as one year old.

The round follows a $12.5M Series A, announced in 2022 and also co-led by Catalyst and Genoa. Together, the two venture rounds total $38.5M. Before the Series A, Epitel also disclosed receiving more than $7.5M in grants from the NIH and the Epilepsy Foundation. That brings disclosed venture funding and grant support to at least $46M, although Epitel did not publish a total funding figure or a valuation for the new round.

Why EEG Access Is the Market Problem

Electroencephalography records electrical activity in the brain, but access to the equipment and trained specialists required to perform and interpret EEG remains uneven. A 2023 peer-reviewed study of 4,550 U.S. hospitals found that only 1,241, or 27.3%, were EEG-capable in 2018, putting a concrete number behind the access problem.

Access is only part of the challenge because seizures rarely occur on a predictable schedule. They may happen days or weeks apart, and short monitoring windows can miss the event clinicians need to evaluate. Longer monitoring increases the opportunity to capture meaningful evidence, but it also generates substantially more data for specialists to review.

How REMI Changes the Monitoring Model

REMI uses wearable sensors to capture and wirelessly transmit EEG data in healthcare and ambulatory settings for up to 30 days. The sensors connect through REMI Mobile and transmit data to REMI Cloud, where recordings are prepared for review using qualified EEG-viewing software.

REMI Vigilenz AI for Event Detection analyzes previously acquired REMI EEG recordings and flags sections that may correspond to potential electrographic seizures. That distinction is essential. The AI is designed to assist qualified physicians, not replace them, and Epitel's labeling states that the system does not generate diagnostic conclusions.

The core technical proposition is not simply a smaller EEG device. It is a monitoring platform designed to observe a longer, more representative portion of a patient's daily life, paired with software that helps clinicians identify potentially meaningful events within an extended recording. A 2021 peer-reviewed feasibility study reported promising results for the reduced-channel montage and algorithm-assisted review, but it remained a limited study and should not be interpreted as evidence of broad clinical or commercial success.

Regulation Was One Gate, Adoption Is the Next

Epitel says REMI has received five FDA 510(k) clearances covering remote EEG monitoring and AI-assisted event detection. Current labeling supports REMI monitoring for patients aged one year and older, while REMI Vigilenz AI for Event Detection is indicated for patients aged six years and older.

Those clearances reduce one category of risk while exposing another. Hospitals and neurology practices must still integrate the platform into ordering, setup, data transfer, clinical review, reimbursement, patient support, and follow-up workflows. Even a technically sophisticated system can struggle if deployment proves difficult or if longer monitoring simply creates a larger queue of recordings for specialists to interpret.

That is why the use of proceeds deserves more attention than the headline funding amount. Epitel is investing in sales, marketing, customer experience, distribution, and provider adoption because commercialization in MedTech is an operational challenge rather than a ceremonial milestone following FDA clearance.

Leadership and Investor Context

Steve Pacelli became Epitel's CEO in 2025 after nearly 20 years in operating roles at Dexcom. Founder Mark Lehmkuhle, PhD, transitioned from CEO to CTO, preserving technical leadership while Pacelli assumed responsibility for the company's next phase of commercial growth.

That leadership structure matches Epitel's current priorities. Lehmkuhle brings the neural engineering expertise and product history, while Pacelli contributes operating experience from a medical device company that transformed continuous monitoring into a major commercial category. Success at Dexcom does not guarantee execution at Epitel, but the division of responsibilities aligns with what the Series B is intended to finance.

Catalyst and Genoa have now co-led both the Series A and Series B. Catalyst focuses on early-stage medical technology, while Genoa invests at the intersection of biology and technology. Their continued support is not evidence that adoption will be straightforward, but it does show that the investors most familiar with the company's earlier progress remain willing to finance its commercial expansion.

What This Signals

Epitel's financing reflects a broader shift in medical monitoring from episodic clinical snapshots toward longer-duration data collected closer to patients' everyday lives. Continuous glucose monitoring established that model in diabetes, while remote cardiac monitoring extended it into cardiovascular care. Brain monitoring presents a more difficult challenge because the data is highly specialized, event interpretation is critical, and misplaced confidence can have serious clinical consequences.

That makes Epitel's measured approach to AI as important as its use of AI. The strongest version of the product story is not that software replaces neurologists. It is that software helps qualified clinicians navigate much longer recordings and identify the sections that deserve closer review. If Epitel can make that workflow efficient, the platform could expand access without suggesting that complex clinical judgment has become automated.

The $26M Series B gives Epitel the resources to test that proposition at commercial scale. The next meaningful evidence will not come from another funding announcement. It will come from whether provider deployment becomes repeatable, patient access expands, and extended EEG monitoring fits naturally into clinical practice rather than remaining a specialized novelty.